Elsewhere on Ulster
This project is funded by:
Glioblastoma is the most aggressive primary brain tumour in adults and usually recurs because cancer cells remain within the surrounding brain after surgery. ChemoSeed® is a biodegradable implant developed by CRISM Therapeutics that is placed directly into the tumour resection margin to provide sustained local delivery of irinotecan.
Irinotecan is converted to its substantially more potent active metabolite, SN-38. This PhD will investigate whether glioblastoma cells convert irinotecan to SN-38 more efficiently than normal brain cells, potentially providing tumour-selective treatment while limiting damage to healthy tissue.
You will use established and patient-derived glioblastoma models, normal brain cells, three-dimensional tumour models and advanced analytical methods to quantify irinotecan uptake, SN-38 formation and tissue penetration. You will investigate the enzymes and cellular pathways responsible for differences in drug activation and identify potential biomarkers that could predict response to ChemoSeed.
Subject to the relevant approvals, you will also analyse tumour samples, pharmacokinetic data, imaging and clinical outcomes from CRISM’s Phase II glioblastoma trial. These findings will be used to study relationships between tumour biology, systemic drug exposure, implant placement and patterns of recurrence. Laboratory and clinical data will then inform a research model for patient-specific ChemoSeed treatment planning.
This collaborative project offers interdisciplinary training in cancer pharmacology, drug metabolism, LC–MS/MS, molecular biology, three-dimensional tumour models, clinical data analysis and computational modelling. You will spend at least three months working with CRISM Therapeutics and gain direct experience of industrial drug development, clinical translation, regulatory strategy, intellectual property and commercialisation.
Please note: Research Proposal - 5 pages in total
The proposal must include:
Please also note that the use of AI in generating the research proposal is prohibited.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Biomedical Sciences/Pharmacy and Pharmaceutical Sciences, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission.
If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship.
In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
PhD Scholarships are available for this project and will cover:
To be eligible for these scholarships applicants must: be a UK or Irish national; or have pre-settled or settled status; or have indefinite leave to remain or enter.
Applicants should also meet the residency criteria which requires that they have lived in the EEA, Switzerland, the UK or Gibraltar for at least the three years preceding the start date of the research degree programme i.e. September 2027.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year, or part-time equivalent, funded from any source, including self-financing students, are NOT eligible to apply for an award.
Students in full-time employment are not eligible for an award.
Due consideration should be given to financing your studies.
Part-time PhD scholarships may be available at a 0.5 pro rata rate of the full-time scholarship, which would require a six-year registration period.
The University will award a successful candidate one of the following scholarships for the project, depending on the funding available at the time an admissions offer is made:
Please note that the Terms and Conditions for scholarships are subject to change for 2027/28.
1. Abdelnabi D, Lastakchi S, Watts C, et al. Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model. Drug Delivery and Translational Research. 2024;14:3070–3088. https://doi.org/10.1007/s13346-024-01524-x
2. McConville C, Lastakchi S, Al Amri A, Ngoga D, Fayeye O, Cruickshank G. Local delivery of irinotecan to recurrent GBM patients at reoperation offers a safe route of administration. Cancers. 2024;16(17):3008. https://doi.org/10.3390/cancers16173008
3. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clinical Cancer Research. 2002;8(8):2605–2611. PubMed: 12171891
4. Metz MZ, Gutova M, Lacey SF, et al. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem Cells Translational Medicine. 2013;2(12):983–992. https://doi.org/10.5966/sctm.2012-0177
5. Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. Journal of the National Cancer Institute. 2015;107(8):djv132. https://doi.org/10.1093/jnci/djv132
Submission deadline
Friday 8 January 2027
04:00PM
Interview Date
between 8 - 16 February 2027
Preferred student start date
13 September 2027
Telephone
Contact by phone
Email
Contact by email